FIELD: immunology.
SUBSTANCE: there are presented antibodies binding with human alpha-synuclein. Also disclosed is an antibody conjugate with a shuttle module, a pharmaceutical composition and use of the antibody.
EFFECT: present invention can find further application in therapy of synucleinopathy and Parkinson's disease.
8 cl, 16 dwg, 9 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2697098C1 |
HUMANIZED ANTIBODIES THAT RECOGNIZE ALPHA-SYNUCLEINE | 2012 |
|
RU2743738C2 |
ANTIBODIES AGAINST TRANSFERRIN RECEPTOR HAVING INDIVIDUALIZED AFFINITY | 2016 |
|
RU2729416C2 |
PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
ANTIBODIES TO LAG3 | 2018 |
|
RU2778053C2 |
AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
ANTIBODIES AGAINST ALPHA SYNUCLEIN | 2018 |
|
RU2787039C2 |
HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
AFUCOSYLATED FIBROBLAST GROWTH FACTOR FGFR2IIIB RECEPTOR | 2014 |
|
RU2740714C2 |
Authors
Dates
2020-04-15—Published
2014-11-18—Filed